Ospedale San Raffaele
Ospedale San Raffaele is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1-Positive Squamous Cell Carcinoma of the Head and Neck
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A single arm, open label, clinical study of cryopreserved autologous CD34+ cells transduced with lentiviral vector containing human ARSA cDNA, for the treatment of early onset Metachromatic Leukodystrophy (MLD)
Sponsor Orchard Therapeutics (Europe) Limited
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available5 trial-level findings · Read insights
- The study was authorized and conducted at a single clinical site in Italy, and all treated subjects received OTL-200 in Italy.
- The planned sample size was based on feasibility in rare MLD rather than statistical considerations.
- Protocol version 6 expanded eligibility to permit enrollment and treatment of early-juvenile MLD at early symptomatic stages before rapid disease progression.
- Protocol version 7 specified arrangements for remote follow-up visits, including assessments by local healthcare professionals or teleconferencing.
- Protocol version 8 reduced required study long-term follow-up to a minimum of 5 years and allowed rollover to a 15-year post-treatment follow-up study.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with Early Alzheimer’s Disease
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A multi-center, randomized, active controlled clinical trial to evaluate the efficacy and safety of OTL-203 in subjects with mucopolysaccharidosis type I, Hurler syndrome (MPS-IH) compared to standard of care with allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Sponsor Orchard Therapeutics (Europe) Limited
- Start (EU)
- Latest update
- Estimated end
A randomized, multicenter, double-blind, Phase 3 study to investigate the safety and efficacy of belrestotug in combination with dostarlimab compared with placebo in combination with pembrolizumab in participants with previously untreated, locally advanced, unresectable or metastatic PD-L1 selected non small cell lung cancer (GALAXIES LUNG 301)
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Phase I/II clinical trial of hematopoietic stem cell gene therapy for the treatment of Metachromatic Leukodystrophy
Sponsor Orchard Therapeutics (Europe) Limited
- Start (EU)
- Latest update
- Estimated end
- Not reported
An open label, non-randomized trial to evaluate the safety and efficacy of a single infusion of OTL-200 in patients with Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD)
Sponsor Orchard Therapeutics (Europe) Limited
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Ospedale San Raffaele?
The 2026-10-09 snapshot links Ospedale San Raffaele to 9 distinct CTIS trials. Recorded services include Laboratory services, Brain magnetic resonance imaging, "Evaluation of sulfatide accumulation and presence analysis white myelinated fibers", Clinical Chemistry, Clinical Haematology, Clinical microbiology, among 9 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Ospedale San Raffaele?
The most frequently recorded therapeutic areas are Otolaryngology, Solid Tumor Oncology, Genetic and Congenital Disorders, Haematological Malignancies. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Ospedale San Raffaele conducted?
The linked trials record locations in 21 countries, including Italy, Germany, Spain, France, Norway. These are trial locations, not confirmed office locations or countries where Ospedale San Raffaele delivered services.
What can this page tell me about Ospedale San Raffaele's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Ospedale San Raffaele. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Ospedale San Raffaele S.r.l.